Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Working Toward Medicare Formulary PBMs Can Use, McClellan Says

Executive Summary

U.S. Pharmacopeia will make sure its model Medicare formulary guidelines "work" for prescription drug plan sponsors as it constructs the final version, Centers for Medicare & Medicaid Services Administrator Mark McClellan says

You may also be interested in...



Caremark May Offer Medicare Rx Plan If Risk Is Minimized, CEO Says

Caremark will consider offering a Medicare stand-alone prescription drug plan if the financial risks for such plans are reduced under final guidelines

Caremark May Offer Medicare Rx Plan If Risk Is Minimized, CEO Says

Caremark will consider offering a Medicare stand-alone prescription drug plan if the financial risks for such plans are reduced under final guidelines

Dual-Eligible Switch Poses New Barriers To Drug Access – Consultant

Low-income seniors may face new barriers to obtaining prescription drugs after Medicare assumes responsibility for their coverage, Southeastern Consultants President Mary Kay Owens said at an IIR Medicaid conference in Denver

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel